Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 15/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.37 |
| ▸ | PI4KA | P42356 | 2/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409234 | 0.81 | ADORA2A (0.50) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL19733383 | 0.79 | ADORA2A (0.47) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL3490619 | 0.77 | LIMK1 (0.44) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL22432874 | 0.76 | ADORA2A (0.51) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL6925128 | 0.72 | ADORA2A (0.43) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19376297 | 0.72 | LIMK1 (0.41) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL30582556 | 0.72 | ADORA2A (0.43) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12621162 | 0.70 | LIMK1 (0.39) | LIMK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL8820773 | 0.70 | PIK3CD (0.41) | LIMK1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24499994 | 0.69 | LIMK1 (0.41) | LIMK1ADORA2AADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20130035334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130018060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130012525-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYLICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120329130-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8236812-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120184013-A1 | Inhibitors of BMX non-receptor tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. A DELAWARE CORPORATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-7732454-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012525-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | LIMK1 618/4885ADORA2A 4718/4885ADORA1 4858/4885 |
| US-20130035334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | LIMK1 2238/4885ADORA2A 696/4885ADORA1 780/4885 |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | LIMK1 546/4885ADORA2A 3542/4885ADORA1 4537/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
| US-20130018060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | LIMK1 546/4885ADORA2A 3542/4885ADORA1 4537/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | LIMK1 517/4885ADORA2A 1298/4885ADORA1 2328/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | LIMK1 919/4885ADORA2A 4471/4885ADORA1 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.